Immatics Nv share price logo

Immatics Nv Share Price

NASDAQ: IMTX

Small Cap

$10.19

-0.23

(-2.21%)

as on

Immatics Nv Stock Performance

as on November 1, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $10.06
    $10.63
    downward going graph

    1.28%

    Downside

    4.32%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.3
    $11.25
    downward going graph

    67.62%

    Downside

    10.40%

    Upside

    downward going graph

Immatics Nv share price movements today

Previous Close
$10.42
Open
$10.41
Volume
697.1K
Day's Low - High
$10.06 - $10.63
52 Week Low - High
$3.3 - $11.25

Immatics Nv Historical Returns

1 Month Return
+ 13.22 %
3 Month Return
+ 57.25 %
1 Year Return
+ 9.22 %
3 Year Return
-12 %
5 Year Return
-1.83 %

Immatics Nv Stock Fundamentals & Key Indicators

Check Immatics Nv market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.3B

EPS (TTM)

-1.9057

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-78.3M

Revenue (TTM)

130.1M

Profit Margin

-57.45%

Return On Equity TTM

-17.54%

Immatics Nv vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Immatics Nv with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Immatics Nv image
Immatics Nv
BUY$1.3B-1.83%NA-57.45%
Insmed Incorporated image
Insmed Incorporated
BUY$40.4B475.59%-16.34-264.83%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$59.4B270.85%-505.15-12.96%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$107.7B104.25%29.8431.86%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$68.7B19.91%15.6732.13%

Stock Returns calculator for Immatics Nv Stock including INR - Dollar returns

The Immatics Nv stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Immatics Nv investment value today

Current value as on today

₹1,14,924

Returns

₹14,924

(+14.92%)

Returns from Immatics Nv Stock

₹9,218 (+9.22%)

Dollar Returns*

₹5,706 (+5.71%)

Analyst Recommendation on Immatics Nv Stock

Based on 14 analysts

BUY

92.86%

Buy

7.14%

Hold

0.00%

Sell

Based on 14 analysts, 92.86% of analysts recommend a 'BUY' rating for Immatics Nv. Average target price of $14.29

Immatics Nv Share Price Target

Get share price movements and forecasts by analysts on Immatics Nv.

What analysts predicted

28.69%UPSIDE

Target Price

$14.29

Current Price

$10.19

Analyzed by

14 Analysts

Target

$14.29

Immatics Nv target price $14.29, a slight upside of 28.69% compared to current price of $10.19. According to 14 analysts rating.

Immatics Nv Stock’s Investor Sentiment and Interest

Search interest for Immatics Nv Stock has increased by 79% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:79% versus previous 30 day period

Immatics Nv Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
10
24
6
17
33
20
56
58
20
4
Gross Profit
-19
-5
-26
-18
-1
20
56
58
20
4
Operating Income
-26
-14
-33
-27
-13
-26
0
0
-35
-53
EBITDA
-22
-22
-31
-24
-10
-14
0
46
-37
-68
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
1
1
1
1
3
3
3
3
3
3
Income Before Tax
-19
-24
-26
-26
-1
-17
-2
43
-40
-71
Income Tax Expense
-4
0
0
0
1
0
6
-1
0
-1
Net Income
-16
-26
-28
-28
-3
-19
-9
46
-43
-70
Net Profit Margin
-154.38%
-110.09%
-447.00%
-164.24%
-10.09%
-96.09%
-16.95%
79.75%
-214.48%
-1485.07%

Immatics Nv Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
4
20
38
39
182
58
163
Gross Profit
-34
-24
-43
-59
69
-70
163
Operating Income
-34
-33
-69
-86
29
-101
-38
EBITDA
-31
-29
-64
-83
50
-88
34
Interest Expense
0
0
0
0
1
0
0
Depreciation
2
3
4
5
6
7
12
Income Before Tax
-32
-32
-229
-93
42
-96
21
Income Tax Expense
-2
0
0
1
4
-2
6
Net Income
-35
-35
-278
-107
39
-105
15
Net Profit Margin
-834.06%
-172.05%
-733.84%
-273.45%
21.71%
-179.63%
9.77%

Immatics Nv Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-24
-26
-26
-3
-18
-8
44
-39
-70
Operating Cash Flow
-6
-30
79
-32
-33
-33
-58
-34
-39
Investing Cash Flow
-16
-70
59
-243
69
67
-47
46
64
Financing Cash Flow
36
49
0
175
0
0
146
0
0
Change in Cash
12
-46
135
-96
36
31
47
6
13

Immatics Nv Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-32
-229
-93
37
-94
15
Operating Cash Flow
70
-85
-81
100
18
-158
Investing Cash Flow
-5
-15
7
-209
-31
-152
Financing Cash Flow
-1
207
-2
123
84
319
Change in Cash
63
104
-74
15
69
18

Global Institutional Holdings in Immatics Nv

Funds
Holdings
T. Rowe Price Investment Management,Inc.
15.08%
Suvretta Capital Management, LLC
9.9%
Baker Bros Advisors LP
8.37%
Perceptive Advisors LLC
7.72%
RTW INVESTMENTS, LLC
5.73%
See all

Insights on Immatics Nv

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, IMTX stock has moved up by 15.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Insmed Incorporated has given 1009.8% return, outperforming this stock by 1019.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Insmed Incorporated has given 184.3% return, outperforming this stock by 172.6%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 44.86M → -70.34M (in $), with an average decrease of 132.7% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 56.25M → 4.73M (in $), with an average decrease of 70.7% per quarter

About Immatics Nv

immatics is a clinical-stage biopharmaceutical company active in the discovery and development of t-cell redirecting immunotherapies for the treatment of cancer. our transformative product candidates are - best in class - adoptive cell therapies and bispecific tcr molecules. these products are directed against tumor targets that have been identified and validated by immatics'​ proprietary and world-leading xpresident® technology. our mission is to bring the power of t-cell redirecting immunotherapies to cancer patients. quick facts - 150 team members - >100 targets covering 20 major solid and liquid tumors - about 80% of discovered targets are novel - 2 proprietary technology platforms - 8 proprietary development programs, thereof 2 in the clinic in 2017 - multiple partnered programs - raised more than $230m in cash in five financings read more about immatics on our homepage: https://immatics.com/ find us on twitter and xing: twitter: http://bit.ly/2dfbpre xing: http://bit.ly/2e1kkpv l
OrganisationImmatics Nv
HeadquartersPaul-Ehrlich-Strasse 15, Tübingen, Germany, 72076
IndustryHealth Technology
CEODr. Harpreet Singh Ph.D.
E-voting on sharesClick here to vote

Key Management of Immatics Nv

Name

Title

Dr. Harpreet Singh Ph.D.

CEO, MD, Member of Management Board & Executive Director

Dr. Rainer Kramer Ph.D.

Chief Business Officer & Site Head Munich

Dr. Hans-Georg Rammensee Ph.D.

Co-Founder & Member of the Scientific Advisory Board

Mr. Cedrik M. Britten M.D.

Chief Medical Officer

Mr. Jordan Silverstein

Head of Strategy

Dr. Venkat Ramanan Ph.D.

Chief Financial Officer

Dr. Toni Weinschenk Ph.D.

Co-Founder & Chief Innovation Officer

Mr. Steffen Walter Ph.D.

Chief Operations Officer

Mr. Edward A. Sturchio

General Counsel & Secretary

Dr. Carsten Reinhardt M.D., Ph.D.

Chief Development Officer

FAQs

What is Immatics Nv share price today?

Immatics Nv share price today is $10.19 as on at the close of the market. Immatics Nv share today touched a day high of $10.63 and a low of $10.06.

What is the 52 week high and 52 week low for Immatics Nv share?

Immatics Nv share touched a 52 week high of $11.25 on and a 52 week low of $3.3 on . Immatics Nv stock price today i.e. is closed at $10.19,which is 9.42% down from its 52 week high and 208.79% up from its 52 week low.

What is Immatics Nv's market capitalisation today?

Immatics Nv market capitalisation is $0.00T as on .

How to invest in Immatics Nv Stock (IMTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Immatics Nv on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Immatics Nv Shares that will get you 0.1472 shares as per Immatics Nv share price of $10.19 per share as on November 1, 2025 at 1:29 am IST.

What is the minimum amount required to buy Immatics Nv Stock (IMTX) from India?

Indian investors can start investing in Immatics Nv (IMTX) shares with as little as ₹88.719 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹887.19 in Immatics Nv stock (as per the Rupee-Dollar exchange rate as on ). Based on Immatics Nv share’s latest price of $10.19 as on November 1, 2025 at 1:29 am IST, you will get 0.9814 shares of Immatics Nv. Learn more about fractional shares .

What are the returns that Immatics Nv has given to Indian investors in the last 5 years?

Immatics Nv stock has given -1.83% share price returns and 21.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?